NewsBenzinga独占：CalamosビットコインETFの上昇余地は40％超え、トップ幹部が明かす投資家が無視できない注意点 独占：CalamosビットコインETFの上昇余地は40％超え、トップ幹部が明かす投資家が無視できない注意点 Benzinga 2026.10.16 17:14 (GMT+0) Open on Benzinga Other news Nasdaq Tumbles Over 2%, Records Weekly Loss: Investor Sentiment Weakens, Fear & Greed Index Moves to ‘Extreme Fear’ Zone Fifth Third Bancorp, Cleveland-Cliffs and 3 Stocks to Watch Heading Into Monday SpaceX Launch Could Create a Giant ‘Jellyfish’ in the Sky Over the East Coast Monday Reported Saturday, AbbVie Says Rinvoq Sustains Crohn’s Endoscopic Remission Of 47.1%-64.2% At Week 144 Through About Four Years, Skyrizi Sustains Ulcerative Colitis Endoscopic Remission Of 38.8%-53.5% At Week 96 At UEGW Reported Sunday, Lilly Brings Updated Phase 3 Selpercatinib Data Versus Cabozantinib Or Vandetanib In RET-Mutant Medullary Thyroid Cancer To ESMO 2026, Alongside Sofetabart Mipitecan, Olomorasib And Abemaciclib Presentations Reported Sunday, AbbVie Plans ESMO 2026 Update Showing ABBV-706 Achieved 56% ORR And 12.4-Month Median OS In 2L+ Small Cell Lung Cancer, With 82% ORR In 2L-Only Patients
Nasdaq Tumbles Over 2%, Records Weekly Loss: Investor Sentiment Weakens, Fear & Greed Index Moves to ‘Extreme Fear’ Zone
Reported Saturday, AbbVie Says Rinvoq Sustains Crohn’s Endoscopic Remission Of 47.1%-64.2% At Week 144 Through About Four Years, Skyrizi Sustains Ulcerative Colitis Endoscopic Remission Of 38.8%-53.5% At Week 96 At UEGW
Reported Sunday, Lilly Brings Updated Phase 3 Selpercatinib Data Versus Cabozantinib Or Vandetanib In RET-Mutant Medullary Thyroid Cancer To ESMO 2026, Alongside Sofetabart Mipitecan, Olomorasib And Abemaciclib Presentations
Reported Sunday, AbbVie Plans ESMO 2026 Update Showing ABBV-706 Achieved 56% ORR And 12.4-Month Median OS In 2L+ Small Cell Lung Cancer, With 82% ORR In 2L-Only Patients
